BPMC News and Press, Blueprint Medicines Corporation From 02/06/20

CAMBRIDGE, Mass. , Feb. 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m...

CAMBRIDGE, Mass. , Feb. 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has extended th...

Researchers at BMO Financial Group have initiated coverage of four companies in the biotech space, with one gaining an “outperform” rating. In an email to clients sent on Tuesday (January 28), the bank confirmed that its research analyst George Farmer will now cover BioMarin Ph...

Acadia Healthcare (NASDAQ: ACHC ) resumed with Equal Weight rating and $36 (11% upside) price target at Stephens. More news on: Acadia Healthcare Company, Inc., BioMarin Pharmaceutical Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Blueprint Medicines (NASDAQ: BPMC ) has priced its public offering of 4,710,144 common shares at $69 per share. More news on: Blueprint Medicines Corporation, Healthcare stocks news, Read more ...

Introduction Blueprint Medicines ( BPMC ) is a precision oncology biotechnology company. Lead indications include gastrointestinal stromal tumors (GISTs) and systemic mastocytosis ((SM)). Blueprint's lead drug, avapritinib, targets KIT and PDGFR kinases, making it an appropriate candidate ...

Alexis Borisy, one of the biopharmaceutical industry's most successful entrepreneurs, recently raised $200 million to launch a new company called EQRx. While the amount raised isn't unusual, the mission driving EQRx has raised eyebrows: Bring down exorbitant drug prices. Another Borisy-founded ...

Blueprint Medicines Corporation (NASDAQ: BPMC ) formally sets out its corporate goals for 2020. More news on: Blueprint Medicines Corporation, Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , Jan. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced corporate goals for 2020, which provide a path to achieve the compan...

Deals and Financings Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics (GLYC) novel E-selectin-based immunotherapies in China for leukemia. Apollomics, which was incubated by OrbiMed Asia, will be responsible for developing uproleselan and GMI-1687 in...